Kardégic (acetylsalicylic acid) is primarily used for managing specific, high-risk conditions where a supportive effect on the cardiovascular system is needed. The core therapeutic benefit of the medication is applied in contexts that require long-term supportive management. It is considered relevant in the supportive management of conditions marked by increased physiological stress in at-risk patients.

---

Supportive Management in High-Risk Cardiovascular Scenarios

This medicine is applied across domains where additional symptomatic support is needed for patients in conditions where functional stability becomes affected. It helps address symptoms related to systemic imbalance and contributes to easing the overall symptom load associated with heightened physiological activity in these critical contexts. This includes use in conditions presenting with recurrent or episodic manifestations and those marked by a heightened systemic burden.

“It provides support that helps ease the overall symptom burden, which assists patients to cope more steadily with difficult vascular episodes.”

Quick Fact: Support for Heightened Physiological Activity

---

Promoting Stability Against Episodic Vascular Events

Kardégic is relevant for easing symptoms that may become disruptive during flare-ups and is used when groups of symptoms appear or fluctuate. It is applied in clinical settings that involve acute or disruptive symptom patterns, which helps maintain a sense of stability when symptoms are more noticeable.

---

Long-Term Assistance for Vascular Symptom Control

Commonly used across conditions presenting with recurrent or episodic manifestations, this medicine provides support that helps ease the overall symptom burden, which assists patients to cope more steadily with difficult vascular episodes. It provides supportive relief when symptoms interfere with daily functioning, supporting general well-being during symptomatic phases.

Eligibility for Kardégic (DL-Lysine acetylsalicylate), a prescription anti-thrombotic agent, is strictly defined by regulatory authorities and is generally limited to adult patients (aged 16 and over) with confirmed cardiovascular risk.

Contraindications (Must NOT Use)

Use is absolutely contraindicated in patients with the following conditions, as stated in official product labels:

• Hypersensitivity to Acetylsalicylic acid (ASA), salicylates, or NSAIDs.
• Active or recurrent gastrointestinal ulcers or hemorrhage.
• Severe hepatic or severe renal impairment.
• Hemorrhagic diathesis or active pathological bleeding.
• Third trimester of pregnancy (from the 24th week).

Age and Physiological Restrictions

Population	Eligibility Status (Regulatory)
Children & Adolescents (<16)	Generally not recommended; contraindicated for viral infections due to Reye's Syndrome risk.
First/Second Trimester Pregnancy	Restricted; use only if clearly necessary and under specialist supervision.
Breastfeeding	Generally not recommended for regular or high-dose use.

Caution Required

Special caution and monitoring are required for older adults (geriatric patients) and individuals with a history of asthma, nasal polyps, gout, or moderate hepatic or renal impairment.

Interactions with other medicines and products

Kardégic (Acetylsalicylic acid) has documented interaction patterns with several medicinal products and substances, as defined in official regulatory documents. These interactions are classified based on pharmacodynamic or pharmacokinetic outcomes.

Co-administration with Methotrexate at doses of 15 mg/week or greater is an official contraindication due to a pharmacokinetic mechanism that significantly reduces Methotrexate renal clearance, leading to a heightened risk of toxicity. The combination with Oral Anticoagulants (such as Warfarin or Heparin) is not recommended in individuals with a history of gastro-duodenal ulcers, as this carries an additive pharmacodynamic risk of major haemorrhage.

Specific timing separation is mandatory for certain non-steroidal anti-inflammatory drugs (NSAIDs). To prevent pharmacodynamic interference that can weaken the antiplatelet effect, Ibuprofen (immediate-release) must be taken at least 8 hours before or 30 minutes after the ingestion of aspirin.

Official prescribing information also documents interactions that alter drug exposure. Aspirin can reduce the renal clearance of substances like Digoxin and can displace Valproic Acid or Phenytoin from protein binding sites, potentially intensifying their effects. Combining this medicine with Systemic Glucocorticoids or SSRIs is noted to increase the risk of gastrointestinal bleeding. Caution is also required for patients with G6PD deficiency taking high dosages, and chronic, heavy alcohol use is documented to increase the risk of bleeding events.

Irreversible Blockade of Platelet Aggregation Signaling

The mechanism of the active ingredient (ASA) centers on the permanent chemical inactivation of the Cyclooxygenase-1 (COX-1) enzyme within circulating platelets. The molecule acts as an acetylating agent, forming a covalent bond with the COX-1 enzyme and rendering it non-functional. This blockade interrupts the arachidonic acid pathway, thereby suppressing the synthesis of Thromboxane A2 (TXA2)—the potent molecular signal essential for activating platelets and promoting their aggregation. This molecular step functionally suppresses the platelet's capacity for aggregation signaling.

---

Sustained Suppression of Platelet Aggregation

The anti-aggregatory effect is sustained because mature platelets are anucleated cells; they lack the necessary machinery to synthesize new proteins. Since the original COX-1 enzyme is irreversibly inactivated, the platelet cannot restore its function, meaning the effect lasts for its entire 7 to 10-day lifespan. This mechanism results in a state of diminished capacity for aggregation by reducing the blood's intrinsic tendency toward thrombus formation.

How to use Kardégic (DL-lysine acetylsalicylate)

Kardégic is an antiplatelet medicine containing acetylsalicylic acid (aspirin) and is supplied as a powder for oral solution in single-dose sachets (e.g., 75 mg, 160 mg, 300 mg strengths). Use must strictly adhere to the dosing and administration instructions provided for the medication, which emphasize preparation and schedule.

Official Administration Guidelines

Feature	Instruction
Route of Administration	Oral route (after dissolution).
Standard Dosing Schedule	Once daily (one sachet per day), as directed by the prescribing physician.
Timing in Relation to Meals	May be taken before, during, or between meals, offering flexible daily intake.
Age-Group Restrictions	Generally reserved for adult use; dosing for all ages must follow medical prescription.

Preparation and Procedural Steps

The powder must be correctly prepared before consumption:

1. Empty the entire contents of the sachet (powder) into a clean glass.
2. Add a sufficient amount of water to the glass.
3. Stir the mixture until the powder is fully dissolved, creating a clear solution.
4. Consume the entire solution immediately by mouth.

This required preparation method ensures the medicine is administered correctly by the oral route. The standard regimen dictates once-daily administration for long-term antiplatelet treatment.

Note on Missed Doses: Instructions for managing a missed dose should be clarified with the prescribing doctor. Treatment duration is generally long-term but is determined by the physician based on the patient's condition.

Research evidence / Overview of studies for Kardégic

---

Evidence for use after a heart attack or unstable angina (Acute Coronary Syndrome)

Research has examined the use of Kardégic during the period immediately following a serious vascular event, such as a heart attack or during conditions associated with acute or disruptive episodes like unstable angina. The studies were conducted during periods of increased symptom activity and typically focused on very short-term outcomes describing episodic or acute changes. The overall research describes patterns where use of this medication was associated with patterns observed concerning certain immediate, serious events when used right after the event. Comparative evidence is lacking for some of the newer treatment approaches.

Evidence for use in long-term prevention after a vascular event (Secondary Prevention)

Clinical trials have explored the long-term, daily use of this medication in patients who have previously experienced a heart attack or stroke. These large-scale studies were evaluated in people living with conditions marked by functional limitations over many years. The research examined whether long-term use was associated with the incidence of future serious events, which are outcomes related to systemic or functional imbalance. It is important to understand that these findings describe group patterns, not personal outcomes. Research provides context but does not determine whether an individual will respond similarly.

Long-term studies and follow-up

Long-term studies have monitored patient outcomes over several years to assess the long-term patterns observed in patients. This research explores how outcomes evolved over the long-term in the studied populations. It is important to note that long-term effects are not fully established beyond the observation period of the longest studies. While some studies have long follow-up durations, there is limited information for long-term outcomes that extend for many decades. The connection between changes in a patient's overall health or the presence of new comorbidities and the observed long-term responses is an area where research is ongoing.

Evidence in special populations

Kardégic was studied for use in a broad range of individuals, but evidence for certain subgroup findings are uncertain. Specifically, the evidence derived from studies focusing on very older adults with complex health profiles is often more limited. Research dedicated to populations who are pregnant, or who have specific serious pre-existing conditions, evidence remains limited. The results apply only to the populations studied in the major trials, which may not fully represent all special populations.

What is still uncertain about Kardégic

Research continues to address several areas of uncertainty. In some trials, findings were mixed regarding certain secondary outcomes related to physical discomfort or quality of life indicators. The need for more head-to-head evidence comparing this specific formulation to other standard options remains an area of uncertainty. Furthermore, there are gaps in the evidence for various sub-groups, especially those with specific conditions involving periods of heightened symptoms. This means that certainty remains low for some very specific patient profiles and that data are still emerging.

Common questions about Kardégic (FAQ)

Q: What is Kardégic (acetylsalicylic acid) used for?

A: Kardégic is used to treat certain conditions related to blood clotting, such as following a heart attack (myocardial infarction) or to prevent a stroke in people who have already had a transient ischemic attack (TIA). It belongs to a group of medicines called platelet aggregation inhibitors, which help to prevent blood cells called platelets from sticking together and forming harmful clots. It is sometimes referred to as a blood thinner, but its specific action is anti-platelet.

Q: How should I take Kardégic?

A: You should take Kardégic exactly as your doctor has prescribed. The specific dosing and frequency depend on the condition being treated and your individual health needs. Kardégic usually comes in powder form in sachets that need to be dissolved in a glass of water, or as effervescent tablets. It is generally recommended to take the medication with food to help reduce the risk of stomach irritation. Do not crush or chew tablets unless specifically instructed by your doctor.

Q: What are the common side effects of Kardégic?

A: Common side effects may include stomach upset, nausea, heartburn, or indigestion. Less commonly, it can cause more serious issues like bleeding (such as nosebleeds, or bleeding gums) or stomach ulcers. Tell your doctor immediately if you experience signs of severe bleeding (e.g., black or bloody stools, vomiting blood) or severe allergic reaction (e.g., rash, swelling of the face or throat, difficulty breathing).

Q: Can I take other medications with Kardégic?

A: It is crucial to inform your doctor or pharmacist about all other medications you are taking, including over-the-counter drugs, supplements, and herbal remedies. Some medications can interact with Kardégic, potentially increasing the risk of bleeding (e.g., other blood thinners or NSAIDs like ibuprofen) or affecting how well Kardégic works. For example, taking Kardégic with other non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal side effects.

Q: What should I avoid while taking Kardégic?

A: Avoid consuming alcohol excessively while taking Kardégic, as this can increase the risk of stomach bleeding. Unless directed by your healthcare provider, you should also avoid taking other medications containing aspirin or NSAIDs (like ibuprofen or naproxen) as they may increase the risk of side effects. Inform your doctor or dentist that you are taking Kardégic before any surgery or dental procedure, as they may instruct you to temporarily stop the medication to reduce the risk of bleeding.

Q: What happens if I miss a dose of Kardégic?

A: If you miss a dose of Kardégic, take it as soon as you remember. However, do not take a double dose to make up for the missed one. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. If you are unsure what to do, contact your doctor or pharmacist for advice.

Q: Is Kardégic safe to take during pregnancy or while breastfeeding?

A: The use of Kardégic during pregnancy and breastfeeding should be discussed with a doctor. The risks and benefits must be carefully evaluated. Generally, high doses of aspirin, the active ingredient in Kardégic, are not recommended during the third trimester of pregnancy due to potential risks to the fetus. Small amounts of aspirin pass into breast milk, and while low doses may be considered safe in some circumstances, a healthcare professional must make the final determination based on your specific situation.

Q: How long will I need to take Kardégic?

A: The duration of treatment with Kardégic is highly dependent on the medical condition it is being used to prevent or treat. For conditions like the secondary prevention of stroke or heart attack, treatment may be long-term, often for many years or indefinitely, under the guidance of your physician. Do not stop taking Kardégic without first consulting your doctor, as this could increase your risk of a serious cardiovascular event.

How to Store and Dispose of Kardégic?

Official regulatory information defines specific requirements for storing and discarding this medicine to maintain product stability and safety.

Storage and Handling Requirement	Official Instruction
Temperature	Store below 25 C or 30 C (check local packaging).
Protection	Keep the product in the original carton or package to protect it from light and moisture.
Child Safety	Always keep this medicine out of the sight and reach of children.
Prepared Solution	The oral solution should be used immediately after being prepared.

For disposal, the product must not be discarded with household waste or poured into water systems. Unused or expired medication should be returned to the pharmacy or disposed of through approved local take-back schemes to protect the environment.